Saturday 17 October 2026 Export NVCT’s income statement to Excel — free account

Nuvectis Pharma, Inc.

In the quarter to June 2026, EPS was flat and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

18.48 0.45 −2.38%

Follow NVCT

Alert me

Market cap: $618.0M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.33

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	3	—	—	—	—	—	—	2	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 9.82%

Capital & Financial Ratios $m

Market Cap 617.95

Revenue —

Net Income (27.85)

Free Cash Flow (19.51)

Net Debt (22.16)

Current Ratio 1.68

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 47.77

Past 5Y EPS Growth —

This Y EPS Growth 20.96%

Next Y EPS Growth (10.38%)

Next Y revenue growth —

Next 5Y EPS Growth 2.54%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 93.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	19	19	32	22
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	0	0	0
	19	19	32	22

	2023	2024	2025	Q'26
Payables	3	2	6	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	9	13	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	9.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	(5)	—	—	—
’25	(4)	(3)	(4)	(4)	(16)
’24	(4)	(3)	(2)	(2)	(12)
’23	(5)	(4)	(3)	(4)	(16)
’22	(3)	(3)	(4)	(4)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	(5)	—	—	—
’25	(4)	(3)	(4)	(4)	(16)
’24	(4)	(3)	(2)	(2)	(12)
’23	(5)	(4)	(3)	(4)	(16)
’22	(3)	(3)	(4)	(4)	(14)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	(0.30)	—	—	—
’25	(0.27)	(0.30)	(0.44)	(0.31)	(1.32)
’24	(0.25)	(0.26)	(0.24)	(0.36)	(1.11)
’23	(0.27)	(0.38)	(0.37)	(0.41)	(1.43)
’22	(0.32)	(0.28)	(0.42)	(0.48)	(1.51)
’21	(0.01)	(1.43)	(1.04)	(0.55)	(3.02)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	3.08	7.14	4.44	5.33	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	20.92	18.65	12.10	11.52
People
People	Employees	—	—	—	—	—	8	11	13	13	13
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	—	0	(13)	(19)	(22)	(19)	(26)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	—	0	(13)	(19)	(22)	(19)	(26)
	Depreciation	—	—	—	—	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	0.00	(3.02)	(1.51)	(1.43)	(1.11)	(1.32)
	Cash flow	—	—	—	—	0.00	(2.23)	(1.07)	(1.03)	(0.72)	(0.73)
	Capex	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	—	0.00	(2.23)	(1.07)	(1.03)	(0.72)	(0.73)
	Book value	—	—	—	—	0.00	(2.58)	1.12	0.78	0.57	0.84
	Shares, m	—	—	—	—	4	4	13	16	17	22
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(10)	(14)	(16)	(12)	(16)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	—	—	—	—	—	(10)	(14)	(16)	(12)	(16)
Balance, $m
Balance, $m	Working capital	—	—	—	—	0	3	14	12	10	18
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	—	—	—	—	—	(6)	(20)	(19)	(19)	(32)
	Shareholders’ equity	—	—	—	—	0	(11)	14	12	10	18
Returns, %
Returns, %	ROA	—	—	—	—	0.00	(387.26)	(141.05)	(112.45)	(100.55)	(114.76)
	ROIC	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	0.18	233.98	(1,188.73)	(168.51)	(173.41)	(205.30)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
AVTX Avalo Therapeutics, Inc.	$644.1M	— (loss-making)	— (loss-making)	−70.14% (below 0%: shrinking)	n/m	+75.70% (above 0%: growing)	55.73%	0.00%	Compare
WVE WAVE Life Sciences Ltd.	$628.6M	— (loss-making)	— (loss-making)	−73.88% (below 0%: shrinking)	n/m	−17.59% (below 0%: shrinking)	100.00%	(3,248.33%)	Compare
CLYM Climb Bio, Inc.	$626.6M	— (loss-making)	—	—	n/m	+3.73% (above 0%: growing)	—	0.00%	Compare
NVCT Nuvectis Pharma, Inc.	$618.0M	— (loss-making)	—	—	n/m	−34.57% (below 0%: shrinking)	—	0.00%
SLDB Solid Biosciences Inc.	$615.5M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−39.56% (below 0%: shrinking)	0.00%	0.00%	Compare
ZVRA Zevra Therapeutics, Inc.	$609.9M	10.5×	10.5×	+53.25% (above 0%: growing)	−88.71% (below 0%: shrinking)	+670.87% (above 0%: growing)	96.16%	42.30%	Compare
PHAT Phathom Pharmaceuticals, Inc.	$606.8M	— (loss-making)	— (loss-making)	+88.02% (above 0%: growing)	n/m	+96.86% (above 0%: growing)	79.68%	(5.34%)	Compare
OLMA Olema Pharmaceuticals, Inc.	$601.1M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$621.1M	—	—	−33.32%	—	+4.07%	79.68%	0.00%

All 614 Biotechnology stocks →

Nuvectis Pharma, Inc. (NVCT) key facts

Nuvectis Pharma, Inc. (NVCT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NVCT traded at $18.48, a market capitalization of $618.0 million.
Return on equity was −205.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.